Abstract
摘要
相似文献
1
Gliptins: bullous pemphigoid.
Prescrire Int. 2015 Mar;24(158):70.
2
A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors.
JAMA Dermatol. 2013 Feb;149(2):243-5. doi: 10.1001/jamadermatol.2013.1073.
3
A case of bullous pemphigoid ınduced by vildagliptin.
Cutan Ocul Toxicol. 2017 Jun;36(2):201-202. doi: 10.1080/15569527.2016.1211670. Epub 2016 Aug 11.
4
Bullous pemphigoid induced by vildagliptin: a report of three cases.
Fundam Clin Pharmacol. 2015 Feb;29(1):112-4. doi: 10.1111/fcp.12083. Epub 2014 Jun 9.
5
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
MMW Fortschr Med. 2014 Jul 24;156(13):74-5.
6
[Therapeutic use and adverse events of incretin-related drugs].
Nihon Rinsho. 2012 May;70 Suppl 3:699-702.
7
Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
Dermatology. 2016;232(2):249-53. doi: 10.1159/000443330. Epub 2016 Jan 28.
8
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
J Am Acad Dermatol. 2018 Mar;78(3):592-595. doi: 10.1016/j.jaad.2017.09.051. Epub 2017 Oct 4.
9
Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
Prescrire Int. 2013 May;22(138):121.
10
Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
Int J Dermatol. 2018 Jul;57(7):810-816. doi: 10.1111/ijd.14005. Epub 2018 Apr 23.
Zotero 插件